News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Trevena, Inc. (TRVN) Appoints Julie H. Mchugh And Barbara Yanni To The Board Of Directors


7/1/2014 11:59:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Julie H. McHugh, former president of Centocor and chief operating officer at Endo Health Solutions, and Barbara Yanni, former chief licensing officer at Merck & Co., have joined Trevena’s Board of Directors. The two directors replace Terrance G. McGuire and David F. Solomon who are stepping down from the Board following the Company’s recent initial public offering.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES